Physician profile
Patrick A Masters
NPI 1073507836
$656.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $48.00 · 2021: $224 · 2022: $98.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $290.89 | 2019-2022 | |
| Janssen Biotech, INC. | $96.89 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.15 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.87 | 2019-2020 | |
| Allergan, INC. | $26.04 | 2019 | |
| Ucb, INC. | $22.20 | 2019-2020 | |
| Olympus America INC. | $19.31 | 2021 | |
| Celgene Corporation | $14.71 | 2021 | |
| Merck Sharp & Dohme LLC | $12.79 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.09 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.65 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$4,253.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.